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ABSTRACT

Neurodegenerative disorders are conditions that mainly affect the brain and
the central nervous system (CNS). Each disease type is characterised by loss of
function which results from death of a particular region. Interestingly enough, most of
the time disease pathology is due to loss of specific cell types in the CNS. These
pathological conditions have both high economic costs and social implications for
society. To treat such conditions, either the lost cells must be replaced or the cells
surrounding the damaged tissue must be induced to undergo repair to replace the lost
cells. The former looks more achievable whereas the latter is problematic as the CNS
has limited ability to regenerate. For cell replacement therapies, stem cells hold much
promise in particular bone marrow stromal stem cells (BMSSCs).
Bone marrow stromal stem cells are phenomenal in terms of their plasticity,
their ability to renew themselves and their availability. Just about every possible use
of BMSSCs has been proposed from diverse fields, but little success has been
achieved in same fields. BMSSCs have been used successfully for bone marrow
transplants and to regenerate whole organs for cell replacement therapies. However
current research has focused on differentiation of BMSSCs into neural tissue for cell
replacement therapies for neurodegenerative disorders has had little success.
The initial approach was to optimise conditions for the growth and
differentiation of BMSSCs. Once optimal conditions were characterised, experiments
to induce differentiation of BMSSCs only produced a_ mixture of neuronal cells.
Ideally for cell replacement therapy, only a single type of cell lost in the disease
process needs to be replaced.
Pax7 is a key transcription factor that drives neural differentiation and
migration of neural cells during development. It is also thought to determine neural
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differentiation in the tectum, where it specifically drives the fate of precursor cells
towards a neural lineage. Upregulation of the transcription factor Pax7 in stem cells
may induce these stem cells to differentiate towards neural differentiation. Since Pax7
specifies neural cell fate and not any other cell type in the CNS, transfected cells
should differentiate into neurons similar to those found in the tectum. It is
hypothesised that transfecting stem cells with Pax7 would create a novel method of
differentiating stem cells into a homogeneous population of neurons. The
differentiated cells could then be used as cellular material for cell replacement
therapies.
In this project a variety of stem cells, P19 cells, NIH3T3 cells and BMSSCs
were transfected with Pax7 and assessed for neural differentiation. P19 and NIH3T3
transfected cells clearly showed differentiation along a neurogenic lineage,
specifically towards the neurons of midbrain. Sadly, the BMSSCs did not survive the
transfection process and further optimisation of conditions is required to achieve
neural differentiation of BMSSCs.

Key words: bone marrow stromal stem cells, differentiation and cell replacement

therapy.
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CHAPTER!

INTRODUCTION

1

NEURAL INDUCTION AND DIFFERENTIATION OF STEM
CELLS USING THE DEVELOPMENTAL GENE PAX7
1.1 Hypothesis
Pax7 induces stem cells to differentiate into a homogeneous population of neurons
in vitro.
1.2 Aims
1.2.1

To stably transfect P19, NIH3T3 and Bone Marrow Stromal Stem
Cells (BMSSCs) with a full length Pax7 eDNA transcript (Pax7d).

1.2.2

To analyse neuronal differentiation of Pax7+ stem cells.

1.2.3

To compare neural differentiation of three different Pax7+ cell lines
(P19, NIH3T3 and BMSSC).

1.3 Background
Most neurodegenerative disorders are due to loss of a specific neural cell type
in the central nervous system (CNS). Attempts to repair the damaged CNS have
seen the development of cell replacement therapies. These therapies attempt to use
embryonic stem cells or neural stem cells to replace neurons lost in injury or
neurodegenerative disorders (Snyder and Olanow, 2005). However current cell
replacement therapies utilise embryonic or foetal neural stem cells which are
undifferentiated and are not fully characterised. Recently a lot of effort has been
made to differentiate neural and embryonic stem cells in vitro which can then be
utilised in cell replacement therapies. While these cells appear promising, there
are limitations due to the source of the cells, cell plasticity, tissue compatibility
and ethical implications. In an attempt to overcome these problems, an alternative
source of cells is being developed, namely Bone Marrow Stromal Stem Cells
(BMSSCs) that can be derived from the patients own bone marrow (Holden and
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Vogel, 2002; Moore and Quesenberry, 2003). BMSSCs are easily accessible, have
the ability to differentiate into various cell types, are tissue compatible and have
few ethical considerations. Recent studies have shown that it is possible

to

differentiate BMSSCs into neurons (Sanchez-Ramos et al., 2000; Woodbury et al.,
2000) but the differentiated stem cells are a mixture of different neuronal cell
types (Azizi et al., 1998; Sanchez-Ramos et al., 2000; Woodbury et al., 2000). It is
anticipated that in many cell replacement scenarios, it will be important to achieve
a homogeneous population of the specific neuron cell type lost to disease or injury
so that the function of the CNS can be restored.
Recently our laboratory has demonstrated that Pax7 transfected into the P19
stem cell line was able to induce more than 95% neural differentiation (Thomas et
al., 2004; Ziman et al., 2001). Moreover the differentiated cells were of one
specific neuron cell type when characterised by specific neural markers (Thomas
et al., 2004). Pax7 encodes a transcription factor that is crucial for midbrain neural
specification during development. Therefore Pax7 may successfully induce stem
cell differentiation along a neurogenic lineage in vitro.

1.4 Sig11iticance
In this project we stably transfected various stem cells with the gene encoding
the transcription factor Pax7, and assessed differentiation of stem cells into a
homogenous population of midbrain specific neurons., A variety of stem cells were
transfected and the transfected stem cells were fully characterised using general
neuronal markers as well as specific markers for midbrain neurons. This study
also address the issue of achieving a homogeneous population of neurons derived
from BMSSCs which other studies have failed to achieve. The outcome includes
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the differentiation of stem cells into a homogeneous population of neurons that are
specific to the midbrain. These experiments also provide the first step towards
achieving a population in vitro differentiated cells that can be used for cell
replacement therapies for neurodegenerative disorders and brain injuries
associated with the midbrain.
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CHAPTER2

BACKGROUND TO THE STUDY

5

2.1 Neurodegenerative disorders
2.1.1

The problem

Neurodegenerative disorders are variable in their aetiology (Table 2.1) and often
the causes are not clearly established. It is thought that both genetic and
environmental factors contribute towards the outcome of the disease (Bertram and
Tanzi, 2005). A common characteristic of many neurodegenerative disorders is the
partial loss of neuronal function during disease onset followed often by neuronal
death and complete functional loss in the final stages of the disease. Interestingly,
most neurodegenerative disorders are characterised by loss of a single neural cell type
in the CNS. For example Parkinson's disease (PD), which is of particular interest to
this project, results from the loss of neurons of the midbrain. PD is characterised by
the specific loss of dopaminergic neurons in the midbrain, substantia nigra which
controls motor function. The onset of PD is clinically characterised by partial tremors
of the hands, arms, legs and jaws. There is also stiffness of limbs and postural
instability (Schapira, 1999). As the disease progresses more dopaminergic neurons are
lost and the clinical symptoms become more pronounced and drug dependency
increases (Schapira, 1999).
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Table2.1 Summary of neurodegenerative disorders that result from the loss of a single
neuronal type in the CNS and the characteristics of replacement cells (Barker et al.,
2003).
Disorder
Cause of neurodegenerative Target replacement cells
disorder
Parkinson's disease Loss of dopaminergic neurons Nigrostriatal dopamine
neurons
Oligodendrocyte in CNS
Multiple sclerosis
CNS oligodendrocyte

Amyotrophic
lateral sclerosis
Huntington's
disease
Alzheimer's
disease
Frontotemporal
dementia

Schwann cells in PNS
Loss of alpha motor neurons

Schwann cells in PNS
Replacement of alpha neurons

Loss of neurons in basal
ganglia and cerebral cortex

Replacement of basal ganglia
and cerebral cortex specific
neurons
Diffused neuronal replacement

Deposition of amyloid causing
death of neuronal tissue
Loss of neurons in frontal and
temporal lobes ofthe brain

Replacement of frontal and
temporal lobe neurons

A second important characteristic of many neurodegenerative disorders is the
accumulation of protein in the neural tissue which results in cell death (Bilen and
Bonini, 2005). Although the accumulation of protein in PD is not well characterised,
in other neurodegenerative diseases, such as Alzheimer's disease, the disease
symptoms are due to the accumulation of beta amyloid in the neural tissue (Verdile et
al., 2004). Other form of brain disorders such as damage due to physical or chemical
induced injury can affect specific brain regions. Damaged neurons do not self
regenerate, so the lost neurons need to be replaced to restore the function of the
particular brain region.

2.1.2 Current treatment
Most of the current treatments for neurodegenerative disorders are aimed at
relieving the symptoms rather than repairing the damaged tissue and curing the
disease (Armstrong and Barker, 2001). For example during the onset of PD, the
symptoms are mild and the base line treatment is dopamine-replacement. Levodopa is
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particularly effective during early stages, however as the disease progresses,
dopamine replacement does not provide any therapeutic benefits (Schapira, 1999).
Neurodegenerative disorders are more common in elderly patients and there
are serious complications associated with polypharmacy in elderly patients. Long
term over dependency on drugs results in less therapeutical benefits and more side
effects. For these and other reasons, most research is now aimed at stem cell
replacement therapies.
Two definitive ways to treat neurodegenerative disorders are:
1.

Stop or reduce the protein accumulation that results in cell death or,

2.

Replace the cells that have been lost.

Replacing the lost neural cells seems to be a more feasible option, as cell death has
already occurred when the disease is diagnosed.

2.1.3

Cell replacement therapy

Cell replacement therapy involves transplanting embryonic stem cells or adult
stem cells at the site of injury to facilitate regeneration of the damaged tissue, and has
generated much interest as a means of treating neurodegenerative disorders. For
successful transplant therapy, the lost cells should have modulatory action that does
not require complex and precise patterns of connectivity (Bjorklund and Lindvall,
2000). Cell replacement therapy is therefore a feasible solution for neurodegenerative
disorders that result from loss of a single type of neuron in the CNS, such as PD
(Barker et al., 2003).
There are different approaches towards treating neurodegenerative disorders using
cell replacement therapies. The first approach is to stimulate already existing neural
stem cells in the CNS to proliferate and differentiate. This treatment is non-invasive
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and overcomes the need for immunosuppression (Falk and Frisen, 2005). The second
approach, that of neurodegenerative cell replacement therapies was initially trialled
using undifferentiated stem cells transplanted into the damaged CNS. It was assumed
that the undifferentiated transplanted cells would differentiate into appropriate neural
types depending on the micro-environment of the CNS. The studies by Azizi and
colleagues (1998) clearly demonstrated that rat mesenchymal stem cells, isolated from
bone marrow and infused into the rat brain, successfully engrafted, migrated and
survived (Azizi et al., 1998), albeit in very low numbers. However very few cells
differentiated into neurons.
A more recent approach has been to differentiate cells in vitro and then
transplant them into the CNS to restore the functional deficiencies caused by
neurodegenerative disorders. Through those approaches, a variety of neurological
disorders can be treated but the most progress has been made in treating PD.
Promising but variable results have also been obtained by transplanting
aborted foetal tissue from the embryonic midbrain (Bjorklund and Lindvall, 2000).
However there have been a number of setbacks with this approach: several foetuses
are required to obtain sufficient cells, plus there are ethical concerns over the use of
foetal tissue (Falk and Frisen, 2005). From the results of their experiment, though it
appears that transplanting undifferentiated neuroblast to replace those that have
degenerated in PD is a feasible approach to restore functional integrity of the
nigrostriatal dopamine system, for patients that do not

~espond

well to medical and

pharmacological therapy (Olanow et al., 1996).
Several studies have now been performed using embryonic stem cells, foetal
neural stem cells as well as adult stem cells in animal models. There is great support

9

from these studies for stem cell therapies for neurodegenerative disorders especially
PD (Kim et al., 2002; Studer, 1998)

2.1.4 Stem cells from adult tissue
In the mid 19th century, Cohnheim suggested that all adult stem cells reside in the
bloodstream (Cohnheim, 1867). The hypothesis has been an issue of immense
discussion and research since then. Recent observations have shown that small, stemlike cells with considerable plasticity are found in a variety of adult tissues including
muscles, fat, liver, synovial membrane and the brain (Ferrari et al., 1998; Mezey,
2000; Petersen et al., 1999). Those cells self renew and also differentiate during tissue
repair. This has validated Cohnheim's hypothesis. It is clear that stem cells found in
most tissues are replenished to a small extent by stem cells found in the marrow
(Prockop et al., 2003).
Unlike other cells in the body, adult stem cells are characterised by two distinct
properties: self renewal and the ability to differentiate into mature cells (McKay,
1997; Weissman, 2000). When a stem cell divides, it undergoes asymmetric cell
division resulting in one stem cell and one differentiated mature cell (Majka et al.,
2005), thus reserve populations of stem cells are maintained for further cell division.
Several types of stem cells exist; totipotent stem cells from the zygote, from which
both embryo and placenta are produced; pluripotent stem cells which give rise to only
the embryo, and multipotent stem cells which give

ri~e

to the three genn layers:

endoderm, mesoderm and ectodenn. Finally stem cells within adult tissues are
generally committed stem cells which give rise to cells of a particular tissue (Lemoli
et al., 2005). From one cell at fertilisation to billions of cells in an adult, cells undergo
continuous differentiation and replacement. But not all cells in the body differentiate;
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some remain as undifferentiated primitive precursor cells and upon damage to the
tissue, help in the regeneration of the tissue (Johansson et al., 1999; Lemoli et al.,
2005).
The major cell types in the CNS are neurons, astrocytes and oligodendrocytes.
They are derived during development from neuronal stem cells formed in the
regenerative zone along the entire neuraxis (Gage, 2000; McKay, 1997). Since the
previous decade, the adult mammalian neural system was considered to be nonrenewable tissue (McKay, 1997), but this principle has been challenged by studies
which have shown that neuronal progenitor cells found in the CNS are capable of cell
division (Falk and Frisen, 2005).
The first evidence of neural stem cells in the brain came from the in vitro
culturing of adult brain cells. Cells were cultured in the presence of growth factors
and a small number of cells proliferated to form neuropheres. These cells were then
able to differentiate into neurons, astrocytes and oligodendrocyte, thus showing
characteristic of true stem cells (Reynolds and Weiss, 1996; Richards et al., 1992). In
addition, the observed changes in neurons in the adult brain of songbirds, important
for the annual change of song patterns, provided further evidence of addition of
neurons in the mature brain (Nottebohm, 2004). Newly generated neurons in the adult
brain are derived from neural stem cells formed in the sub-ventricular zone and
hippocampus (Gage, 2000).
Although the adult human brain demonstrates regene_ration in specific areas, there
is a limit to the extent to which the CNS will regenerate. It is believed that this is due
to lack of sufficient endogenous factors to activate endogenous neural stem cells in
sufficient amounts to repair the damaged CNS (Peterson, 2002). Recent experiments
suggest that BMSSCs can be induced to differentiate into neural cells (Grove et al.,
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2004). Thus BMSSCs could be used for neural cell transplant therapies if BMSSCs
could be induced to differentiate into a specific neural cell type.

2.1.5 Limitations of cell replacement therapies
Several studies have shown that transplanted stem cells do not necessarily
differentiate into a required specific neural cell type. For functional benefits,
transplanted cell should be able to integrate into the mature brain and establish
appropriate connections (Falk and Frisen, 2005). Cell replacement therapies should
therefore be used to replace cells that do not require complex connections and have
relatively simple functions. The other challenge for successful cell replacement
therapy is to control cell differentiation to produce only one specific cell type. The
other challenge is to control proliferation once the cells are transplanted in the CNS;
otherwise tumour formation results (Falk and Frisen, 2005). Once the differentiated
cells have been transplanted in the CNS, they should lose their proliferative properties
and become tissue committed cells which cannot proliferate further.
Though the stem cell isolation methods are well established, a major setback is
that little is known about the safety of transplanting stem cells subjected to current
isolation methods. Generally these cells are labelled with antibodies and conjugated
with fluorescent dye or magnetic particles and sorted using fluorescence activated cell
sorting (FACS) or a magnetic field. These methods tend to employ chemicals and
dyes such as Hoechst 33342 and Rhodamin 123 (Goodel! et al., 1996; Ratajczak et al.,
1998). The effects of these dyes on the stem cells are not yet established and could
change the primitive fate of the stem cells. This could limit the ability of stem cells to
differentiate along a particular lineage and may be a reason why little success has
been achieved in differentiating stem cells into homogenous populations of neurons.
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BMSSCs can also be sorted in accordance with their property of adherence to
plastic (Rando and Blau, 1994). BMSSCs isolated by adherence to plastic are not
actually homogeneous but the cells become homogeneous in appearance when grown
in culture for longer and they lose their haematopoietic properties (Ono et al., 2003).

2.1.6 The ideal cells
As previously discussed (1.3), a major limitation of cell replacement therapy is
sourcing of the cells. The cells predominantly used are embryonic stem cells and
neural stem cells. However the ideal replacement cells for successful cell replacement
therapy should meet six conditions:
1.

Lots of cells should be available for harvesting with no risk of depletion.

2.

The cells should be compatible with indefinite expansion in vitro without
loss of plasticity.

3.

The harvested cells should be able to differentiate into a homogeneous
population of cells.

4.

The cells should posses plasticity or be able to undergo transdifferentiation into specific mature neurons able to integrate into the
mature brain upon transplantation.

5.

There should be no risk of cell rejection after transplantation.

6.

There should be no risk of cell proliferation and formation of tumours.

BMSSCs are ideal cells that would meet all of the above criteria and overcome
major problems that currently face cell replacement therapy. BMSSCs replenish
themselves and can be either harvested from bone marrow or blood, thus are easier to
access than neural stem cells and embryonic stem cells. Transgenic plasticity is a key
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property of bone marrow stem cells; they are able to differentiate into cells that are
phenotypically unrelated to the tissue of origin (Bianco et al., 2001). Lastly, since the
cells are isolated from the patients own bone marrow, they do not pose a threat of cell
rejection and thus no immunosuppression would be required to graft the cells into the
CNS.
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2.2

Bone marrow stromal stem cells (BMSSCs)
2.2.1

BMSSC plasticity

Bone marrow stromal stem cells normally contribute to the regeneration of
mesenchymal tissue such as bone, cartilage, ligaments, tendons and muscles
(Bruder et al., 1997; Ferrari et al., 1998; Petersen et al., 1999). Studies by
Woodbury et al, (2000) and Sanchez-Ramos et al, (2000) have shown that rat
bone marrow can be induced to differentiate into neurons and astrocytes in vitro
and BMSSCs when transplanted into the damaged CNS, have the potential to
migrate and differentiate into neuronal tissue in animal models (Sanchez-Ramos et
al., 2000; Woodbury et al., 2000).
Interestingly BMSSCs transplanted into the brain have a tendency to
differentiate into neurons whereas BMSSCs transplanted into the spinal cord have
a tendency to differentiate into astrocytes (Shihabuddin et al., 2000). This is an
important finding as it indicates that the fate of transplanted BMSSCs is directed
by the micro-environment of the host tissue rather than the pre-programmed fate
of the cells themselves (Spradling et al., 2001; Watt and Hogan, 2000).
Results from our lab suggest that Pax7 is a key micro-environmental factor in
regionalisation and specification of neurons of the superior colliculus (or the
tectum in lower vertebrate). Thus transfecting BMSSCs or any stem cell with

Pax7 could create a similar micro-environment to that found in vivo and induce
differentiation of stem cells into neurons specific to the superior colliculus.
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2.2.2 Ethical considerations
Embryonic stem cells, which are derived from the inner cell mass of the
embryo, are the most totipotent cells and are capable of differentiating into any
cell of the body. The recent controversy surrounding the procurement of
embryonic stem cells has divided people into supporters of therapeutic cloning
and

non~supporters

of therapeutic cloning. Recent legislation permits the use of

these stem cells for therapeutic cloning. However ethical considerations remain a
limiting factor.
There are few, if any, such ethical considerations when harvesting BMSSCs.
The harvesting of BMSSCs is done by withdrawing bone marrow from an adult,
typically patients themselves. It does not involve any long term/irreversible
procedure thus overcoming the ethical considerations associated with the use of
embryonic stem cells.

2.2.3 Supply and availabilitv
The greatest advantage of BMSSCs is the fact that they are readily available in
the blood and in the bone marrow of the adult patient. The cells can be isolated
from blood by il'\iecting a growth factor, colony stimulating factor into the blood
stream of the patient for five days which enhances proliferation of these cells.
Haematopoietic stem cells are then collected through aphresis (Cutler and Autin,
2001).

An alternative way of harvesting BMSSC is by inserting a needle into the
shaft of the femur or tibias and withdrawing bone marrow (Sanchez-Ramos et al.,
2000).

16

BMSSCs have also been harvested from cord blood. The first cord blood bank
was established in 1995 in Australia, allowing patients access to stem cells from
their own cord blood. The practise of cord blood collection is fairly recent and the
storage procedures are complex and expensive (Australian National Pathology
Accreditation Advisory Council., 1999). This places a major limitation on the use
of cord blood derived stem cells relative to the more accessible BMSSCs
harvested from bone marrow.

2.2.4 The risk of cell rejection

When using BMSSCs cell rejection would not arise because the cells are from
the persons own bone marrow. According to the Bone Marrow Donor Institute of
Australia, the only limitation associated with use of patient's own BMSSCs is
that, if there is a genetic defect in BMSSCs since birth, then that defect would also
be present in the BMSSCs and may affect their ability to differentiate into
different lineages. This is an important issue to address in neurodegenerative
disorders like familial Huntington's disease, where a gene defect cause the
disease, and BMSSCs would have the same defect as the brain cells. BMSSCs are
therefore not a solution where a germline mutation is present.
In this project I will investigate the ability of the developmental gene Pax7 to
differentiate stem cells including BMSSCs to a homogeneous population of neural
progenitor cells for later use in cell replacement therapy to repair damage to the
superior colliculus. Pax7 is just one of several Pax genes that could be used for
differentiation of region specific neural cells for cell replacement therapy.
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CHAPTER3

ROLEOFPAX7
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3.1 Role o(Pax genes

Pax7 is one of several Pax genes which encode a family of transcription factors
that are critical during development and organogenesis (Dahl et al., 1997; Mansouri et
al., 1996a). In vertebrates, Pax genes have been conserved over millions of years
(Jostes et al., 1990) and play very important roles in CNS, muscle, thymus, kidney
and pancreatic development during embryogenesis.
The expression of Pax genes in the CNS are region specific, contributing to
regionalisation of the brain during embryogenesis (Stoykova and Gruss, 1994; Ziman
and Kay, 1998). Pax expression is up-regulated during embryogenesis but expression
becomes restricted to specific cells as the embryo moves towards adulthood.
The Pax gene family has nine Pax members which encode Pax proteins that have
a paired DNA binding domain. There are four Pax protein subgroups and their
division into subgroups is based on their relative developmental function and degree
of amino acid conservation (Gruss and Walther, 1992; Jostes et al., 1990; Mansouri et
al., 1996a) refer to figure 3 .1.
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HO

Figure 3.1. Classification showing four subgroups of Pax genes, adapted from
(Mansouri et al., 1996a)

Pax proteins primarily bind to an enhancer DNA sequence in the promoter
region of target genes and regulate expression of the .target gene, whose functional
products control developmental pathways (Kawakami et al., 1997). The importance of
Pax genes has been shown in mutant mice which do not survive to birth and develop

severe deformalities (Chi and Epstein, 2002). Mutations in Pax genes cause failure of
whole organs to develop as demonstrated by Pax3 mutant mice which exhibit neural
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tube defects and multiple neural crest deficiencies (Lang et al., 2000). Moreover,
Pax6 controls the formation of the eye in vertebrates and invertebrates. Pax6

heterozygous mice have a small eye while homozygous mutant mice lack eyes. This
not only proves that Pax6 is required to regulate downstream genes that form the eye
but also indicates that the effects of Pax6 are concentration specific (Halder et al.,
1995; Quiring et al., 1994).
Most Pax genes are expressed as alternate transcripts with variations influencing
the efficiency and specificity of binding by the encoded protein to the target DNA
(Vogan and Gros, 1997). Thus Pax transcription factors exhibit wide functional
diversity and play important roles spatially and temporally to achieve the complex
configuration of the developing embryo.

3.2 The structure of Pax protein
The Pax family of transcription factors have two DNA binding domains and a
protein interaction domain; a paired domain, a homeodomain and a transactivation
domain respectively (Ziman and Kay, 1998). The paired domain consists of six ahelices grouped into two helix-tum-helix (HTH) motifs. The paired domain is 128
amino acids long and is located close to theN-terminal end of the protein (Jostes et
al., 1990) and consists of two sub domains (PAl and RED) each consisting of three ahelices (Bopp et al., 1986). Each sub domain may bind independently to target DNA
sequences. Moreover, the homeodomain may bind independently to DNA or at site
adjacent to those bound by the paired domain. Refer to figures 3.2 and 3.3.
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Figure 3.2. The structure of the Pax protein: The paired domain consists of two subdomains PAI and RED, each with three a-helices (Bopp et al., 1986). The conserved
octapeptide region is located between the paired domain and the homeodomain.

T O

Figure 3.3. Representation of the structure of the Pax protein with the paired domain
(PD), octapeptide motif (OP), homeodomain (HD) and transactivation domain (TD)
indicated. All Pax proteins have a similar structure but vary in the presence of a
complete or partial homeodomain and/or octapeptide (Chi and Epstein, 2002).

3.3 Expression patterns o[Pax genes

Most of the Pax genes are expressed in the spinal cord apart from Paxl, Pax4 and
Pax9 which are expressed in the vertebral column.
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Table3.1: Expression of Pax genes in the CN S and their location. Adapted from
(Underhill, 2000).
Pax gene
Pax]
Pax2
Pax3
Pax4
Pax5
Pax6
Pax7
Pax8
Pax9

Location of expression
Not expressed in CNS, expressed in developing
vertebral colwnn
Midbrain-hindbrain boundary & optic stalk
Mesencephalon
Endocrine pancreas- not in the CNS
Midbrain-hindbrain boundary
Telencephalon
Mesencephalon
Midbrain-hindbrain boundary
Not expressed in CNS, expressed in developing
vertebral colwnn

Though several Pax genes are expressed in the brain during development, it is
the restricted expression of each Pax gene that helps to establish regional boundaries
in the brain.

Pax-3

Pax-2 1 Pax-8
Pax-5

.

Pax-6

.

Pax-7

Figure 3.4. Diagrammatic representation summarising the expression of Pax genes
within distinct boundaries in the embryonic brain. Adapted from (Stoykova and
Gruss, 1994)
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3.4 The (unctiotl o(Pax7 in the CNS

During embryogenesis, Pax7 exhibits discrete expression patterns in the CNS, as
well as in migrating neural crest cells, and condensing somites (Jostes et al., 1990).
Mansouri and colleagues have shown that Pax7 participates in development of neuralcrest-derived cranio-facial structures and skeletal muscle satellite cells by using
knock-out mice (Mansouri et al., 1996b; Seale et al., 2000). Pax7 is expressed
spatially and temporally in the CNS during early embryogenesis (day 8) through to
postnatal development (Jostes et al., 1990) and in adults (Ziman et al., 1997).
Alternate splicing creates alternate transcripts of Pax7, which encode isoforms
with different structures. Each isoform is likely to bind to a different set of target
genes (Ziman and Kay, 1998). Pax7 expresses four alternate transcripts; Pax7a,
Pax7b, Pax7c and Pax7d, which differ by the presence or absence of a trinucleotide

or a hexanucleotide in the paired box. This results in the respective encoded proteins
having one or two extra amino acids included or excluded in the paired DNA binding
domain.
It is the inclusion or exclusion of one, two or none amino acids in the paired

domain that determines the specificity of Pax7 isoforms for their target genes.
Previous studies have shown that while the proportion of alternate transcripts is
similar in brain and muscle, the more frequent combination of transcripts in brain are
Pax7b and Pax7d while in the muscle the more common combination is Pax7a and
Pax7c (Ziman and Kay, 1998). The transcripts

exp~essed

in the brain lack a

hexanucleotide which suggests they may have a role in neurogenesis (Ziman and Kay,
1998). Therefore in this project the Pax7d isoform was utilised as it is the most
abundant transcript and is found predominantly in neural cells (Ziman et al., 1997).
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3.5 Whv transfect stem cells with Pax7?
Pax7 has been shown to participate in neurogenesis of the midbrain during
development. Pax7 is a transcription factor that binds and regulates the expression of
downstream target genes which are likely to be involved in neural differentiation in
the midbrain (Thomas et al., 2006; Thomas et al., 2004; White and Ziman, 2006).

Pax7 is expressed in the mesencephalic alar plate as early as day two during
development and plays a role in tectum development (Jostes et al., 1990; Thomas et
al., 2006; Thomas et al., 2004). In fact, Pax7 may be regarded as a master control
gene for specification of the tectum as it defines the identity of the dorsal alar plate
and ectopic expression of Pax7 in the forebrain induces formation of an ectopic tectal
structure (Matsunaga et al., 2001; Nomura et al., 1998).
Furthermore Pax7 is expressed in the majority of proliferative cells during early
stages of tectal differentiation. However the expression pattern of Pax7 in later stage
tectallaminae is not homogeneous but rather graded which suggests its importance in
establishing tectal polarity and laminar architecture (Thomas et al., 2006; Thomas et
al., 2004). The protein is expressed in graded concentrations, high dorsally and low
ventrally, low rostrally and high caudally (Thomas et al., 2006). Thus Pax7 is
expressed in distinct boundaries within the mesencephalon which helps to establish
tectal regionalisation and polarity in the mesencephalon. It is the spatial and temporal
expression of Pax7 that regulates development of the tectum (Thompson et al, 2006.

In press).

Pax7 is continuously expressed in the retino-recipient precursor laminae of the
tectum with relative changes in Pax7 expression as differentiation occurs. Moreover

Pax7 appears to play a role in the specification of subtypes of neurons destined to
occupy retino-recipient precursor laminae (Thomas et al., 2006).
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Our previous research has shown that stem cells transfected with Pax7 can be
differentiated along a neurogenic lineage (Thomas et al., 2004; Ziman et al., 2001).
Conclusive data showed that a P19 cell line stably transfected with Pax7 resulted in
more than 95% of the cells differentiating along the neurogenic lineage (Ziman et al.,
2001).
Moreover, three days after injury to the tectum (or superior colliculus in
higher vertebrates), there is up regulation of Pax7 which presents a small window of
opportunity for regeneration to occur (Thomas et al., 2006). In organisms capable of
retinal regeneration, up regulation of Pax6 has also been observed; cells enter the cell
cycle and repopulate the damaged retinal cells (Chi and Epstein, 2002). The results of
these studies suggest that there are endogenous mechanisms that may assist with
regeneration of damaged tissue (Thomas et al., 2006; Yamamoto et al., 2001). Other
studies have shown that adult neurogenesis can be stimulated by basic Fibroblast
Growth Factor (bFGF) and Epidermal Growth Factor (EGF) in an adult brain (Gould
et al., 1999; Palmer et al., 1999).
Stem cells have also been shown to differentiate into neurons through growth
factor induction in vitro (Joannides et al., 2003). The major set back with growth
factor induced neuronal differentiation is that differentiated cells are not well
characterised and they are more often a mixture of different neuronal cell types.
Given that Pax7 is the key regulator for neural differentiation in the dorsal
midbrain and is expressed in the damaged brain three days after injury and given that
one of the key reasons for incomplete regeneration of the CNS after damage is due to
lack of sufficient endogenous factors (Peterson, 2002), it is possible that there is
insufficient Pax7 to reach threshold values to cause neural proliferation,
differentiation and repair in the adult midbrain. This study addresses the shortfall of
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endogenous factors that drive neuronal differentiation by up regulating Pax7 in stem
cells that can be used for cell replacement therapies to replace lost neurons.

3.6 Implications o{usingPax7 in stem cells (or cell replacement therapv
The potential to generate a homogeneous population of a particular type of neuron
would enhance cell replacement therapy for diseases caused by loss of a single type of
neuron. The use of a transcription factor that is involved in specification of neurons
during development and which is up regulated during an injury or a disease state, to
differentiate stem cells along a neurogenic lineage, may induce a homogeneous cell
population for cell replacement therapies (Rossi and Cattaneo, 2002).
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CHAPTER4

METHODS AND MATERIALS
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4.1

Cloning o(Pax 7d into pcDNA3.1DIV5-His-TOPO vector.

The vector used for cloning was pcDNA3.1DN5-His-TOPO vector
(Invitrogen) Appendix 1; it generates consistent high gene expression in mammalian
cells compared to other commercially available vectors.
eDNA of Pax7d transcript (Genebank accession number: NM 011039.1
Appendix 2) cloned into pcDNA 3.1N5 HIS TOPO vector was kindly provided by
Rob White (White and Ziman, 2006). Vectors were transfected into E. Coli, plated on
Luria-Bertani (LB) agar plates containing 100

~-tg/ml

of ampicillin, incubated

overnight at 3 7°C. Individual colonies from the plates were selected and grown in Sml
of LB broth overnight at 37°C on a rocker. The pc DNA 3.1N5-HIS-TOPO vector
map is provided in Figure 4.1. The cloned Pax7 sequence is also provided in appendix
2.

Figure 4.1. Graphical representation of the pcDNA 3.1N5 HIS-TOPO vector. Pax7d
was inserted between the two TOPO sites. The vector contains a V5 epitope tag and a
His6 tag. The vector contains a neomycin resistant gene for selection of stable
transfected colonies in mammalian cells.
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Plasmid DNA was isolated using a QIAprep Spin Miniprep Kit (QIAGEN)
according to the manufacturer's instructions. E.Coli containing LB broth was
centrifuged, supernatant removed and the pellet resuspended in 250 J.tl of buffer Pl.
The cells were lysed in 250 J.!l alkaline solution buffer P2 for 5 minutes. The solution
was neutralised using 350 J.tl of buffer N3, mixed gently and centrifuged at 13000rpm
for 10 minutes. The supernatant was then applied to a silica membrane spin column,
and the plasmid DNA was allowed to bind to the silica membrane. RNA and proteins
were removed by centrifuging for 1 minute at 13000 rpm. The silica membrane was
washed twice with buffer PB to remove any other impurities before DNA was eluted
with 50 J.tl of sterile water.
Plasmid DNA (5 J.tl) was loaded with 3 J.tl of loading buffer onto a 1% agarose
gel containing ethidium bromide 0.1 J.tllml and electrophoresed at a constant voltage
of 105 V for 1 hour. A 1 kb ladder was utilised for relative size comparisons. The gel
was visualised on a Gel Doc System (BioRad) and images analysed using the
Quantity One software program (BioRad). DNA concentrations were calculated by
spectrophotometry at a range of dilutions.
To confirm that Pax7 was inserted into the vector in the correct orientation,
the Pax7d insert region was amplified by PCR using the forward primer (F4) 5'CACCGACTCTGGATTCGTCTCCAGCGTG-3', of which the first four bases are
vector specific while the rest of the primer spans the 5' untranslated region of Pax7.
The

reverse

primer,

BGH

reverse

5'-TAGAAGGCACAGTCGAGG-3',

is

complementary to the vector sequence at the 3' end of the Pax7 insert. The melting
temperatures were calculated using a web based primer analyser (Intergrated DNA
technologies,
).
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The PCR reaction was performed with QIATaq (QIAGEN, Australia)
according to the manufacturer's specifications. Briefly, the PCR reaction contained 1x
PCR buffer (15 mM MgC}z), 1x Q-solution, 10 !lM forward primer, 10 !lM reverse
primer, 10 !lM dNTPs, 0.5 units of Taq polymerase per reaction and 50 ng DNA in a
volume of 20 jll. PCR cycle conditions were: Initial denaturation for 3 minutes at
94°C; then 30 cycles of denaturation for 1 minute at 94°C, annealing for 30 seconds at
50°C and 2 minutes extension at 72°C followed by a final extension for 10 minutes at
72°C.
PCR products (5 Ill of sample with 3 Ill of loading buffer) were
electrophoresed on a 1% agarose gel containing ethidium bromide (0.1 !ll/ml). The
gel was run at a constant voltage of 105 V for 1 hour. The gel was visualised and the
image was captured on a Gel Doc System (BioRad). The expected PCR product size
was 1744 bp.

4.2 Ethics
This project involved use of rats to isolate bone marrow stromal stem cells. For
this reason, ethics clearance was obtained from the Animal Ethics Committee at Edith
Cowan University. All necessary protocols were followed so as to cause minimal pain
to. the animals. This project also involved genetic modification to cells and therefore
necessary notification was made to the Institutional Biosafety Committee (IBS) for
classification of the project as an exempt dealing jn accordance with Gene
Technology Act (2001) (IBC ref number: ED.4.2005).
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4.3 Bone marrow extraction
Animal ethics clearance was obtained from Edith Cowan University Animal
Ethics Committee, (approval number 06-A3) prior to purchasing and euthanizing the
animal.
An 8 week old Sprague Dawley Rat (285 grams) was purchased from the Animal
Resource Centre (Murdoch University, Perth). Upon arrival, the rat was euthanized
with Lithabarb (Sodium Pentobarbitone) at a concentration of 15 mg/1 00 grams of
body weight by intra-peritoneal injection (lml injection with 20G needle). Death was
confirmed by lack of breathing and no response after pinching the toes.
Using a surgical scalpel and a scissors, skin and muscles were cut to expose the femur
and tibia, which were then physically detached from the body and cleaned of excess
muscle and tendons. In a Petri dish, the ends of the femur and tibia were cut to expose
the shaft of the bone. Bone marrow was extracted by inserting a 21 G needle and
flushing each bone with 5 ml of a-MEM. The cell suspension was centrifuged at
500rpm for 5 minutes. The supernatant was discarded and the cell pellet resuspended
in 1 ml culture medium. Resuspended cells were grown in T25 culture flasks in 5 ml
of culture medium. Culture medium comprised of a-MEM (Invitrogen), 15 %
knockout serum (Invitrogen), and 2 mM Glutamax (Invitrogen).

4.4

Culture BMSSCs, P19 cells and NIH3T3 cells

BMSSCs isolated as described above, and a BMSSCs cell line (purchased
from Tulane centre for gene therapy, New Orleans), were initially cultured in medium
consisting of a-MEM, knockout serum and Glutamax for one week. Medium was
changed three times a week. The BMSSCs were then cultured in growth medium for
three weeks to obtain a pure population of BMSSCs. Growth medium consisted of
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42%

a~MEM

(Invitrogen), 42% F12 (Invitrogen), 15% knockout serum (Invitrogen)

or fetal calf serum (Invitrogen), 20 ng/ml FGF (Invitrogen), 20 ng/ml hEGF
(Invitrogen) and 100 U/ml penicillin/streptomycin/Fungizone.
Two cell lines were also cultured alongside the BMSSCs for experimental
comparisons. P19 embryonic carcinoma stem cells (passage 12, ATCC, catalogue
number CRL-1825) and NIH3T3 embryonic fibroblast (passage 10, ATCC, catalogue
number CRL-1658) were thawed from frozen stocks and resuspended in 1 ml of
growth medium. Resuspended cells were transferred to T25 culture flasks and grown
in 5 ml of growth medium at 37°C in 5% carbon dioxide. The growth medium was
changed three times a week. P 19 is an embryonic carcinoma stem cell line which has
previously been shown to differentiate into neuronal or muscle cells. NIH3T3 is an
embryonic mouse fibroblast stem cell line commonly used for DNA transfection
studies. The BMSSC line is the preferred choice for cell transplant therapies as both
P19 and NIH3T3 cell lines cause tumours, but are useful for development of in vitro
stem cell models.

4.5

Passaging the cells

When cells reached 90-95% confluency, the growth medium was aspirated
and discarded. Cells were washed with 2 ml of PBS before the addition of 3 ml of
accutase (Chemicon) to detach cells from the flask. The flask was gently tapped to
detach the remaining cells stuck to the flask. Accutase

c~ll

suspension was aspirated

and transferred to a 15 ml falcon tube and centrifuged at 500 rpm for 5 minutes.
Supernatant was discarded, and the cell pellet washed with 1 ml of growth medium.
The cell pellet was then suspended in 1 ml of growth medium. The cell suspension
(200 J..Ll) was then added to a T25 culture flask containing 5 ml of growth medium.
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4.6

Transfection ofBMSSCs, P19 and NIH3T3

One day prior to transfection, cells were seeded at 4-8 x 105 cells per well into
T5 6 well tissue culture plates (Gibco) containing 2 ml of growth medium per well.
Cells at 90-95% confluency were transfected with plasmid DNA (4 IJ.g) isolated as
described in section 1.1, and mixed with 250 !J.l of Opti-MEM I reduced serum
medium (Invitrogen). A 10 !J.l volume of lipofectamine (Invitrogen) was diluted in
250 Ill of Opti-MEM I reduced serum medium and incubated for 5 minutes at room
temperature. Diluted DNA was combined with diluted lipofectamine (total volume
500 !J.l), mixed gently and incubated for 20 minutes at room temperature. Plasmid
DNA -lipofectamine complex (500 !J.l) was added to each well containing cells plus
medium. The contents were mixed by gently rocking the plate back and forth. Cells
were incubated at 37°C in a 5% carbon dioxide incubator for 18-48 hours prior to
testing for gene expression. After 24 hours, transfection medium was replaced with
growth medium containing 1% gentamycin for stable transfection selection.

4.7

SelectingPax7+ stable clones

Cells were visualised under an inverted microscope and individual clones
containing Pax7d, or vector alone were selected from each cell line using sterile
swabs. Individual clones were propagated in growth medium containing 1%
gentamycin. Prior to placing the cells in differentiation medium, expression of Pax7
or vector was confirmed in each clone by RT-PCR and immunocytochemistry. For
each cell line, clones expressing high levels of Pax7 or vector alone were selected for
further experimentation. For each cell line, a total of two clones expressing Pax7 and
two clones containg vector alone were chosen for further experiments, representing a
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total of 4 clones (two Pax7+ and two vector alone) per cell line. Cell transfected
vector alone did not survive the selection process so untransfected cells were utilised
as controls.

4.8

Differentiating the cells

Differentiation medium consisted of 42% a-MEM, 42% F12, 15% knockout
serum and 1OOU/ml penicillin/streptomycin/fungizone. Before transferring cells to
differentiation

medium,

the

cells

were

analysed

using

RT-PCR

and

immunocytochemistry and termed Day 0. Cells were then transferred and cultured in
differentiation medium for 7 days, after which time they were collected for RNA
extraction and RT-PCR analysis or fixed for immunocytochemistry and termed Day 7.

4.9

RNA extraction (or RT-PCR

RNA from the cells was extracted using PureLink Micro-to-midi Total RNA
purification system (Invitrogen) according to the manufactures instructions. Briefly,
cells were pelleted by centrifugation of accutased cells at 500 rpm for 5 minutes. The
cell pellet was washed with PBS and centrifuged at 500 rpm for 5 minutes. The cells
were lysed with 200 f.tl of lysis buffer containing 1% P-mercaptoethanol and mixed
gently. An equal volume of 70% RNAse free ethanol was added and mixed gently.
Then 400 f.tl of lysate was transferred to an RNA binding spin cartridge and
centrifuged at 12000 rpm for 15 seconds. The :flow throl!gh was discarded. A 350 J.tl
volume of wash buffer I was added to the spin cartridge centrifuged at 12000 rpm for
15 seconds and :flow through discarded. A further 700 J.tl of wash buffer I was added
to the spin cartridge, centrifuged at 12000 rpm for 15 seconds and the flow through
discarded. The spin cartridge was placed in a new RNAse free wash tube. 500 J.tl of
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wash buffer II was added, and then the cartridge was centrifuged at 12000 rpm for 15
seconds and the flow through discarded. A further 500

~1

of wash buffer II was added,

the cartridge was again centrifuged at 12000 rpm for 15 seconds and flow through
discarded. The spin cartridge was centrifuged at 12000 rpm for a further 1 minute to
dry the RNA binding membrane. The spin cartridge was placed in an RNAse free
collection tube. RNAse free water (50

~1)

was placed on the RNA column for 1

minute, and then RNA was eluted by centrifuging at 12000 rpm for 2 minutes. RNA
was assessed by gel electrophoresis for quality and the concentration was determined
by spectrophotometry. RNA was stored at -80°C until used in RT-PCR experiments.
RT-PCR was used to assess Pax7 expression and neural differentiation in the
cell line prior to and after transfection. A total of 50 ng of RNA was converted to
eDNA using an Omniscript Reverse Transcriptase Kit (Qiagen): a 20

~1

reaction

contained 4 units Omniscript reverse transcriptase, 1x RT buffer (15 mM MgC12),
dNTPs (5 mM of each dNTP) RNAse inhibitor (10 units/~1) and random hexamers as
primers (10

~M).

The reaction was incubated at 37°C for 1 hour, and 2

was utilised in eaQh downstream PCR. PCR was performed in a 20
contained 1x PCR buffer (15 mM MgCh), 1x Q-solution, 10
~M

reverse primer, 10

~M

~M

~1

~1

of eDNA

reaction which

forward primer, 10

dNTPs, 0.5 units of Taq polymerase per reaction and 2

~1

eDNA. The PCR conditions for all reactions were: 94 °C for three minutes followed
by 45 cycles comprising 94°C for 30 seconds, 52°C- 57°C for 30 seconds, 72°C for
30 seconds and a final extension at 72°C for 10 minutes. Annealing temperatures
ranged form 52°C- 57°C and were specific for each set of primers used in the PCR
reactions.
The PCR products were visualised on 1% agarose gels stained with ethidium
bromide and analysed using the GelDoc system. All RT-PCR reaction products were
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semi~quantified

relative to GAPDH expression levels using software Quantity One

(BioRad). Gene expression levels was analysed in duplicates for each clone of each
stem cell type.
For each clone transfected with Pax7, or for the cells transfected with vector
alone, PCRs were performed on the isolated RNA with gene specific primers (Table
4.1 ). The genes tested were Pax7, neural markers (Neurofilament, Beta Ill tubulin,

MAP2, nestin, Engrailed 2, NCAM and Ephrin A2) or the glial marker GFAP, and
stem cell markers (CD44, CD90 and CDJJB). The summary of gene specific primers
used in R T-PCR reaction is shown in Table 4.1.

Table 4.1. A summary of the genes and primers used in RT-PCR reactions to test
neural differentiation oftransfected cells.
Marker

Product
size
Pax7
CACCGACTCTGGATTCGTCTCCAGCGTG ACAACCATGAGAAACACGGAGC 279bp
224bp
GFAP
TCCTGGAACAGCAAAACAAG
CAGCCTCAGGTTGGTTTCATC
ACCTGTTGGTCTGAAACTCAGC 273 bp
Engrailed 2
TGGATGGAGTGCTCAAAGC
AAGAGAAGGATGTTGGGCTGAG 248 bp
Nestin
GAGTCAGATCGCTCAGATCC
Beta
TCTCACACTCTTTCCGCACG
246bp
III TGGAGCGCATCAGCGTATACTAC
tubulin
TGTTGGACAGGACTATGAACCG 278 bp
NCAM
TACCCTCACCATCTACAACG
342bp
GATGGCTGTGAGGGTTTCTTCC
Neurofilament CAGCAGTTGGAAAATGAACTTC
AGGTACTGTTGAAAGCCTGGC
276bp
CD44
TGACAGGTTCCATTCACCCTCG
259bp
ATGGGCTCAGGAAACAACTG
GACCACATTCTGTCCAAAGC
CDllB
CATAAACCTTGAGTCGCTGGC
413 bp
E_phrinA2
CAACGCTGACCGATACGC
GTGAAGGTCGGTGTGAACG
ATTTGATGTTAGTGGGGTCTCG
233 bp
GAPDH
322 bp
ATCCTTGGTGGTGAAGTTGGC
CD90
AATCCAAGTCGGAACTCTTGGC
Reverse primer 5' to 3'

Forward primer 5' to 3'

4.10

Fixing cells for lmmunocvtochemistry

The cells grown for 0 days or 7 days in differentiation medium were cultured
in 8 well immunocytochemistry chamber slides (Nunc) .. After 24 hours the cells were
washed with TBS thiee times and fixed in 4% paraformaldehyde for 10 minutes. The
cells were washed three times with Tris buffered saline (TBS) and quenched in 3%
hydrogen peroxide for 10 minutes. The cells were again washed with TBS three
times. Non-specific binding was blocked by incubating the cells in TBS I 0.1%
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Triton-X 100 I 3% normal goat serum (NUS) (Invitrogen) and 3% fetal calf serum
(FCS) (Invitrogen) for 1 hour at room temperature. Primary antibodies were applied
overnight at 4°C; primary antibodies were diluted in TBS I O.l%TX I 1% NGS I 1%
FCS. Table 4.2 gives a summary of the primary antibodies and the dilutions used for
immunocytochemical analysis of the cells.

Table 4.2. A summary of the primary antibodies used and their cell type specificity.
Antibody

Company

Raised in/clonality

Pax7

DSHB

Mouse/monoclonal 1/10

NeuN
GFAP
Nestin
Beta III Tubulin
Ki-67
Neurofilament
OX42

Abeam
Chemicon
DSHB
Abeam
Abeam
Chemicon
Abeam

Mouse/monoclonal
Rabbitlpolyclonal
Mouse/monoclonal
Mouse/monoclonal
Rabbitlpolyclonal
Rabbit/polyclonal
Mouse/monoclonal

Dilution

11250
11500
1/100
11500
11250
1/500
1/250

type
Cell
detected
Transfected
cells
Neural
Astrocyte
Stem cell
Neural
Proliferation
Neural
Dendritic
macrophage

Primary antibody was removed and the cells washed with TBS. Secondary
antibody, anti mouse/rabbit (anti-IgG) linked to biotin (LSAB kit DAKO) was applied
for one hour at room temperature, followed by the tertiary antibody, streptavidin
linked to horse-radish peroxidise (HRP) (LSAB Kit DAKO), for one hour at room
temperature. The tertiary antibody was removed; the cells were washed with TBS
three times followed by TNS twice. Cells were visualised by a colour reaction using
diaminobenzidine (DAB) (DAKO). The cells were finally washed with TNS, and
cover-:-slipped using aqueous mounting medium to avoid losing stained cells.
Primary antibodies used were: Pax7 (DSHB); neural markers Neurofilament
(Chemicon), NeuN (Abeam) and Beta III tubulin (Abeam); the cell proliferative
marker used was Ki67 (Chemicon); astrocyte marker was Glial fibrillary acidic
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protein GFAP (Chemicon); the neural precursor marker Nestin (DSHB) and the
macrophage I dendritic cell marker OX42 (Abeam), (see Table 4.2). The cells were
visualised with an Olympus microscope and photographed using a Leica DC300
camera.
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CHAPTERS

RESULTS
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5.1

Cloning Pax.7 into the expression vector

Pax7d previously cloned into the pcDNA3.1 DIV5 HIS-TOPO vector or vector

alone were amplified in E. Coli. Purified vector DNA was run on a 1% agarose gel to
check the DNA purity. The total size of the vector was 5514 bps and the Pax7 insert
was 1560 bps, thus the expected size of the vector plus the insert was 7074 bps.
Circular plasmids adopt multiple structural conformations, which in turn affect the
rate at which they migrate in an agarose gel during electrophoresis. Thus three bands
were visible on the gel, implying that three different structures were adopted by the
circular pcDNA3.1 vector.

11198bp
7126bp
5090bp
4072bp
3054bp

Figure 5.1. Purified vector DNA containing Pax7 or
vector alone control, were electrophoresed on 1%
agarose gel adjacent to a 1 Kb ladder. The size of the
purified product was approximately 7 kilo bases.
Three bands are clearly visible, as expected for
circular plasmids, which adopt different structural
conformations in solution.
-
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5.2

PCR to confirm Pax7 insertion into the vector

PCR was performed on the purified plasmid DNA to confirm the Pax7
insertion. Primers specific to the vector and insert, F4 and BGH, were used for the
PCR. The expected PCR product size was 1748 bp. For the forward primer, only four
base pairs are complementary to the vector and the rest of the primer spans the start of

Pax7. The reverse primer was complementary to the vector; at a position a further 184
base pairs from the end of the Pax7 insert. Thus the PCR product was 4bp plus
1560bp plus 184bp which equals 1748bp.
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4072bp
3054bp
2036bp
l636bp

Figure 5.2. PCR was performed on purified vector
DNA containing Pax7. The product size as
expected was 1748 bp. There was no DNA
detected in the blank (no DNA control).
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5.3

Confirmation o{Pax7 expression in transfected and selected cells
Pl9 cells

After cells were transfected and stably selected, the Pax7 insert was confirmed by
immunocytochemistry. Untransfected P19 cells did not express any endogenous Pax7.
As expected transfected cells express Pax7, confirming Pax 7 expression from the
vector. P19 cells transfected with vector alone did not survive gentamycin selection;
all the P 19- vector cells died due to unsuccessful transfection. Therefore untransfected
P 19 cells were used as a comparative control.

"

Figure 5.3 . A: untransfected P19 cells showing no expression of Pax7. B: P19 cells
transfected with Pax7 detected by immunocytochemistry with Pax7 antibody. Every
single transfected cell expressed Pax7. A representative sample of Pax7 transfected
cells from clone one is shown here. Similar results were obtained for clone two. Scale
bar lO)lm.

The success of Pax7 transfection was crucial for the remaining experiments;
without expression of Pax7 in the cells, the down stream target genes regulated by
Pax7 would not be activated or would only be regulated at basal level. Thus we would

not be able to assess Pax7 induced stem cell differentiation into specific neurons.
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5.4

Gene expression in P 19 cells

After RNA was extracted and converted to eDNA, PCR was performed to
determine which genes were expressed by untransfected P 19 cells, termed basal gene
expression. Stem cells are known to express low levels of a wide variety of genes.
Thus they have wide potential for differentiation, and differentiation is often driven
by micro-environmental factors surrounding the cells (Blondheim et al., 2006). When
a cell starts to differentiate along a particular cell lineage, genes related to that cell
type are up-regulated and the rest of the basal level gene expression is shut down.
Here, testing for basal level gene expression patterns in untransfected P19 cells
indicated that a wide variety of genes were expressed in P19 cells at various
expression levels (Refer to figure below).

489 bp
404 bp
331 bp
242 bp

190 bp
147 bp
110 bp
67 bp

Figure 5.4. RT-PCR for P19 cells to detect basal level gene expression in
untransfected cells. Variable band intensity on the gel for several genes indicated
varied expression levels relative to GAPDH. Untransfected P19 cells did not express
CDllB and expressed only very low levels of Pax7 and NCAM. Blank, no DNA
control, for each set of primers was negative.
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5.5

Gene expression in P19 + Pax7 trans(ected cells

RT-PCR performed on RNA from Pl9 cells transfected with Pax7, indicated
definitive suppression of GFAP and Nestin expression. When the intensity of bands
was quantified, there was a significant difference in gene expression patterns
compared to basal level gene expression levels present in P19 cells (Table 5.1).

489 bp
404 bp
331 bp
242 bp
190 bp
147 bp

110 bp

67 bp

Figure 5.5. The gene expression patterns in P19 cells transfected with Pax7 differed
from those in untransfected Pl9 cells. Expression of GFAP and nestin expression
were significantly reduced in Pax7+ cells. The increased expression of Neurofilament
and Beta III tubulin in Pax7+ cells indicates that Pl9+Pax7 cells have commenced
differentiation along a neurogenic rather than an astrocytic lineage. Pax7 expression
levels increased as did levels of Ephrin A2 and Engrailed 2 - all markers of dorsal
midbrain neurons.
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5.6

Gene expression in P19 + Pax7 transfected cells after 7 days in
differentiation medium
P19 and Pl9+Pax7 cells were grown in differentiation medium containing a-

MEM, F12, knockout serum and antibiotic without EGF and FGF (see section 4.8).
The growth factors were withdrawn to ensure that the changes in gene expression
observed after Pax7 transfection were not due to growth factors. Moreover the growth
factors were used for rapid proliferation of cells, therefore to differentiate the
transfected cells, growth factors were removed from the culture medium.
The gene expression of P19 cells transfected with Pax7 did not change after
seven days in medium without growth factors EGF and FGF. Only Pax7 expression
was dramatically increased. Most other genes remained up or down regulated in
patterns similar to that seen in transfected cells at day 0, but gene expression for most
of the genes was slightly decreased when analysed by band intensity relative to
GAPDH.

489
404
331
242
190

bp
bp
bp
bp
bp
147 bp
110 bp

67 bp

Figure 5.6. RT-PCR for P19 cells transfected with Pax7 and grown in differentiation
medium for 7 days. There was no great difference in gene expression relative to Pax7
transfected cells at day 0. Most genes were in fact slightly down regulated when band
intensity was analysed relative to GAPDH.
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Table 5.1. Semi-quantitative analysis of gene expression levels in P19 and P19+Pax7
transfected cells. Quantity One (Bio-Rad) was used to analyse band intensity relative
to the GAPDH PCR product and used as a measure of fold difference in gene
expression levels.
P19 cells

P19 Pax7 ( 0 days) P19 Pax7 ( 7 Days)

Fold
Difference
10

Pax7

0.1 5

0.66

1.58

Nestin

1.00

1.25

1.56

1.5

Ephrin A2

0.37

2.54

1.44

6

CD90

0.11

2.94

1.57

27

CDllB

Nil

Nil

0.60

0.5

CD44

0.65

1.82

1.50

3

Neurofilarnent

0.30

2.79

1.55

9

NCAM

Nil

1.03

1.47

1.5

Beta III tubulin

0.68

1.94

1.49

2.5

Engrailed 2

0.86

2.85

0.54

3

GFAP

0.60

0.52

0.16

0.25

GAPDH

1.00

1.00

1.00

1

In cells transfected with Pax 7, Pax7 expression increased at day 0 and was
further increased after incubation in differentiation medium for 7 days. Neural genes
were also up regulated, including nestin which is a neural progenitor marker. GFAP
levels decreased after Pax7 transfection, whereas the mature neural markers Ephrin
A2, Neurofilament, NCAM, Beta III tubulin and Engrailed increased in transfected

cells relative to untransfected cells. The results indicate that the P19 stem cells are
likely to differentiate into neurons after transfection with Pax7.
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5. 7

Immunocytochemistry o(Pl9 cells and PJ9+Pax7 cells

1. GFAP
P19 +Pax7

P19

Figure 5.7. Expression of GFAP in untransfected P19 cells and Pax 7 transfected P19
cells. Scale bar 10 ).!m.

2. NeuN
P19
I

P19 +Pax7

.

Figure 5.8. Expression of the neuronal marker NeuN in untransfected P19 cells and
Pax 7 transfected P19 cells. Scale bar 1Oj.!m.
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Immunocytochemistry was performed to detect protein levels in the cells
transfected with Pax7 relative to untransfected control cells. Pax? protein was clearly
evident in transfected cells while no Pax? was detected in untransfected cells (Figure
5.3). Furthermore both transfected and untransfected cells expressed GFAP, an
astrocyte marker (Figure 5.7), however the levels of GFAP in each cell may differ as
indicated by RT-PCR. The levels of GFAP protein in Pax7 transfected cells appears
lower relative to untransfected P19 cells, however this was not quantified.
Expression of NeuN, a marker for mature neurons, is evident m Pax7
transfected cells but was not present in the untransfected cells (Figure 5.8).
Expression ofNeuN is an indication that the cells have exited from the cell cycle and
maturation and differentiation towards a neuron has commenced (Samat et al., 1998).
All the transfected cells expressed NeuN and therefore were on a path of neuronal
differentiation as suggested by protein expression.
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3. Nestin
P19

II

Figure 5.9. Expression of neural precursor marker Nestin in untransfected P19 cells
and Pax 7 transfected P19 cells. Scale bar 1O~m.

4. Beta III Tubulin
P19 +Pax7

P19

..

I

Figure 5.10. Expression of Beta III tubulin m untransfected P19 cells and Pax7
transfected P19 cells. Scale bar lO~m.

50

N estin expresswn appeared reduced in transfected cells compared to
untransfected control cells. P19 stem cells showed expression of nestin at a basal
level, but as the cell differentiated towards a neural lineage, nestin expression
appeared diminished (Figure 5.9). Nestin is an intermediate filament protein
expressed predominantly by neural stem cells and its thought to be an important
marker of early neural cells (Wislet-Gendebien et al., 2003). When a cell is fully
differentiated and matured, nestin is not expressed at all.
Beta III tubulin is a cellular structural protein expressed as five isoforms. Beta
III tubulin is specifically expressed as a structural protein exclusively in neurons (Lee
et al., 1990). Levels of Beta III tubulin in the Pax7 transfected cells increased,
indicating that the transfected cells were differentiating towards a neural lineage
(Figure 5.1 0). Not all untransfected cells expressed Beta III tubulin whereas, by
contrast, all transfected cells expressed high levels of Beta III tubulin.
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5. Ki67

Figure 5.11. Expression of proliferative marker Ki67 in untransfected P19 cells and
Pax7 transfected P19 cells. Scale bar 10~-tm.

6. Neuro(ilament

Figure 5.12. Expression of neuronal marker Neurofilament in untransfected P19 cells
and Pax 7 transfected P19 cells. Scale bar 10~-tm.
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7. OX42
P19

' '·'
~

t.

('

Figure 5.13. Expression of dendretic marker OX-42 in untransfected P19 cells and
Pa.x 7 transfected P19 cells. Scale bar lOj.tm.

Ki67 is a protein that is expressed in the nuclei of proliferating cells. Absent
only in resting cells, cells in the G 1, S, G2, and M phase of the cell cycle express this
marker (Keng and Siemann, 1998). Both Pax7 transfected and untransfected cells
expressed nuclear Ki67 (Figure 5.11 ), indicating that the cells remained proliferative
after Pax7 transfection.
Neurofilament is a structural protein present in neurons, and is expressed by
both early neuroblasts as well as post mitotic neurons.

It is indicative of cell

differentiation towards a neural lineage. Neurofilament is a filament protein
consisting of three forms: light, medium and heavy neurofilament, all of which are
structural proteins found in the cytoplasm of neurons. In Pax7 transfected cells
neurofilament was observed in the cell body and projecting cell processes (Figure
5. 12). In untransfected cells, the expression of neurofilament was restricted to the
region around the nucleus, denoting undifferentiated cells.
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OX-42 is a marker of dendritic macrophages. Both transfected and
untransfected cells did not express any OX-42 (Figure 5.13).
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5.8

Immunocytochemistry o{NIH3T3 cells and Pax7+ NIH3T3 cells
Immunocytochemistry was also performed on NIH3 T3 cells and on NIH3 T3

cells transfected with Pax7 to determine expression of Pax7 and selected genes. The
cells were transfected with Pax7d, and stable clones were selected and analysed for
Pax7 expression as described previously in section 4.6. Vector transfection was

performed but NIH3 T3 cells with vector alone did not survive gentamycin selection.
Untransfected NIH3T3 cells were used as comparative controls.

1 Pax7
NIH3T3 + Pax7

NIH3T3

.. ....
'

'

~·

..

.,

•''

1

J

Figure 5.14. Expression of Pax7 in NIH3T3 untransfected cells compared to Pax7
transfected NIH3T3 cells. Scale bar 1OJ.!m.
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2

GFAP

NIH3T3

~~~----------------------~

NIH3T3 + Pax7

'J

Figure 5.15. Expression of GFAP in NIH3T3 untransfected cells compared to Pax7
transfected NIH3T3 cells. Scale bar lOJJ.m.
3

NeuN

NIH3T3

Figure 5.16. Expression ofNeuN in NIH3T3 untransfected cells compared to Pax7
transfected NIH3T3 cells. Scale bar lOJJ.m.
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4 Nestin

Figure 5.17. Expression of Nestin in NIH3T3 untransfected cells compared to Pax 7
transfected NIH3T3 cells. Scale bar lOJ..Lm.

5

Beta III tubulin
NIH3T3 + Pax7

NIH3T3

I

Figure 5.18. Expression of beta III tubulin in NIH3T3 untransfected cells compared to
Pax 7 transfected NIH3T3 cells. Scale bar lOJ..Lm.

57

6

Ki67
NIH3T3 + Pax7

NIH3T3

Figure 5.19. Expression of Ki67 in NIH3T3 untransfected cells compared to Pax7
transfected NIH3T3 cells. Scale bar lOJ.!m.
7 Neurofilament
NIH3T3 + Pax7

NIH3T3

I

Figure 5.20. Expression ofNeurofilament in NIH3T3 untransfected cells compared to
Pax7 transfected NIH3T3 cells. Scale bar lOJ.!m.
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8

OX-42
NIH3T3 + Pax7

NIH3T3

1

Figure 5.21. Expression of OX-42 in NIH3T3 untransfected cells compared to Pax7
transfected NIH3T3 cells. Scale bar 1o~-~.m.

There was no difference between gene expression patterns of NIH3 T3 cells
and Pl9 cells. Both untransfected cell lines were negative for Pax7 while transfected
cell lines were positive for Pax7; Pax7 protein was present in 80% - 100% of the
cells. Expression of neural markers neurofilament, Nestin, NeuN and Beta III tubulin
increased in NIH3T3 cells after transfection with Pax7 as observed in P19 transfected
cells. In NIH3 T3 transfected cells Ki67 expression appeared increased relative to
untransfected cells. OX-42 was negative in both transfected and untransfected
NIH3T3 cells. Since immunocytochemistry results were consistent with those
obtained from Pl9 cells transfected with Pax7, RT-PCR was not performed on
NIH3T3 cells.
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Similar results in P 19 and NIH3 T3 cells confirmed that previous experiments
(Ziman et al., 2001) in which it was observed that Pax7 induced differentiation ofP19
cells along a neurogenic lineage, were not due to artefacts or an innate property of the
cell line.

5.9

Immunocytochemistry (or rBMSSCs

Immunocytochemistry was performed on rBMSSCs to assess Pax7 and neural
gene expression in untransfected cells. The transfected cells survived two weeks after
transfection but died during selection, therefore no RT-PCR or immunocytochemistry
could be performed on the Pax7 transfected cells.

•
•

A.Pax7

B. NeuN

Figure 5.22. Expression of (A) Pax7 and (B) NeuN in untransfected BMSSCs. No
Pax7 expression was evident whereas NeuN expression was clearly present in the
nucleus. Scale bar 10!-!m.
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A.GFAP

C. Beta Ill tubulin

B. Nestin

I

I

D. Ki67

I

Figure 5.23. Expression of (A) GFAP, (B) Nestin, (C) Beta III tubulin and (D) Ki67.
GF AP was present around the nucleus, with little staining in the cytoplasm. Nestin
was present in the cytoplasm and around the nucleus. Beta III tubulin was present
throughout the cell. Proliferative marker Ki67 was specifically restricted to the
nucleus. Scale bar 1Oj.im.
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,
,

B. OX-42

A. N eurofilament

Figure 5.24. Expression of (A) neuronal marker Neurofilament and (B) dendritic
marker OX-42 in untransfected BMSSCs. Neurofilament is highly expressed and
present only in the cytoplasm. OX-42 was not expressed. Scale bar lOj.tm.

Rat BMSSCs do not express Pax7 (Figure 5.22 A). NeuN was found
expressed in the nucleus of BMSSCs but not in the cytoplasm as expected (Figure
5.22 B). The nuclear expression of NeuN in these stem cells was a surprise. NeuN
expression was confmed to very dark staining regions in the nucleus, possibly at a site
of active chromatin, indicative of basal level expression of NeuN. NeuN is usually
only expressed when a cell exits from neural progenitor cell status and becomes a
fully differentiated neuron (Samat et al. , 1998).
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GFAP was expressed particularly in the cytoplasm but not in the nucleus of
untransfected BMSSC cells (Figure 5.23 A). The staining was evenly spread within
the cytoplasm.
Nestin expression in untransfected cells was in the cytoplasm and specifically
around the nucleus but not in the nucleus (Figure 5.23 B), as expected for a stem cell
line.
Beta III tubulin was expressed evenly throughout the cell at low levels (Figure
5.23 C). Ki67 expression in untransfected cells was specific to the nucleus, with dark
chromatin staining visible (Figure 5.23 D), indicating proliferating cells.
Expression of Neurofilament in untransfected cells was specific to the
cytoplasm. There was no cell body staining and the cytoplasmic staining was evenly
distributed through out the cytoplasm (Figure 5.24 A). By contrast OX-42 expression
was not detected in untransfected cells at all (Figure 5.24 B).
Thus BMSSCs express neural genes at low levels, thus indicating the potential of
BMSSCs to differentiate along a neurogenic lineage.
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CHAPTER6

DISCUSSION
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6.1

Justification (or the use o{Pax7d

In this study, the transcription factor Pax7 was used to induce the
differentiation of stem cells into a homogenous population of neurons. As a
transcription factor, Pax7 regulates the expression of downstream target genes that
determine cell lineage and differentiation. In vivo Pax7 has been implicated in cell
specification of midbrain neurons during embryonic development (Basch et al., 2006).
Given the importance of Pax7 in CNS development we anticipated that by
transfecting undifferentiated cells with Pax7, the cells will be directed along a
neurogenic lineage.
The Pax7 gene encodes several transcripts and each encoded isoform is
believed to have a specific set of target genes, however this remains to be determined
(White and Ziman, 2006). In this project the Pax7d transcript (Appendix 2) was used
in transfections of both P 19 and NIH3 T3 cells.
Although no specific transcript of Pax7 has been assigned an individually
distinct function, in vitro experiments suggest that Pax7d may be important in neural
differentiation. It has been demonstrated that the transcripts Pax7b and Pax7d are
specifically expressed in the brain of adult mice (Ziman et al., 1997). Moreover when
P19 cells were transfected with Pax7d the cells were induced to differentiate along a
neurogenic lineage (Ziman et al., 2001). It is possible that the Pax7d transcript
functions to regulate neural genes in the tectum to specify tectal neural fate (Thomas
et al., 2004; Ziman et al., 2001).
Previously, transfection of P19 cells with either Pax7 or Pax6 resulted in
neural differentiation of the cells. While it was determined that it was the expression
of Pax genes that induced the neural differentiation of the cells, it was thought that
possibly the default pathway of P 19 cells may be neural. Therefore we assessed the

65

neural differentiation of several cell lines following transfection with Pax7. Our
results showed that both gene and protein expression patterns were similar in all the
cell lines assessed. Thus ectopic expression of Pax7 has the ability to induce neural
differentiation in multiple progenitor cell lines.
Expression of Pax7 in multiple transfected cells induced upregulation of
neural genes, indicating that upregulation of neural genes was due to Pax7. Stem cells
were transfected with Pax7 to assess the ability of this gene to induced neural
differentiation for future transplant therapies. Experiments were conducted in P 19
cells, NIH3T3 cells and BMSSCs to compare neural induction in all three cell lines.
Sadly, while the transfection of BMSSCs was successful, the cells did not survive
selection and no further results could be obtained. Future studies will concentrate on
perfecting cell culture and transfection of these cells for future stem cell therapies

6.2

Novel findings

When P19 stem cells were transfected with the gene Pax7, the expression
levels of several genes were altered. The differences in the gene expression and
protein levels were due to the presence of Pax7, since the control cells had little or no
Pax7 expression. It was clear from our results that neural differentiation genes were

upregulated while glial specific genes were down regulated by Pax7.
Neurofilament is a structural protein present in neurons and also serves as a
marker for neural differentiation; increased expression is an indication that the cells
are moving towards neural differentiation. Neurofilament was upregulated in the
presence of Pax7 in transfected cells relative to untransfected cells. Stem cells would
have little or no neurofilament expression, when assessed by immunocytochemistry
and only low levels of neurofilament (basal level expression) were detected by R T-
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PCR in untransfected cells. Both cell lines expressed neurofilament at a higher level
after transfection with Pax7, indicating some differentiation towards a neuronal
lineage.
Further support for this was the upregulation of NCAM in transfected cells.
Neural cell adhesion molecule is a marker of mature migrating neurons. NCAM plays
a vital role in neural cell proliferation and migration during development. It has
important implications in synapse formation between neurons and the establishment
of new connections through cell-cell adhesion. Spatial and temporal expression plays
a pivotal role in neurogenesis during development (Ronn et al., 2000). A long chain of
sialic acid is added to NCAM to form polysialic acid NCAM which is negatively
charged (Kiss and Rougon, 1997). Neural migration is facilitated by the negative
charge due to attachment ofpolysialic acid on NCAM which is a membrane spanning
protein expressed on the neurons to help axonal growth and neural migration.
Attachment of polysialic acid on NCAM prevents any synapse formation and
promotes neural migration. NCAM is therefore an important cell membrane protein
expressed by neurons, in which conjunction with polysialic acid aids neural migration
and synaptogenesis. Our findings indicate NCAM was not expressed at all in the
control untransfected cells but was expressed in transfected cells. NCAM expression
in transfected cells suggested neural differentiation had been induced by the presence
ofPax7.
Further experiments are required to determine" whether increased Pax7
expression in transfected cells, causes increased cell migration due to increased
polysialic acid NCAM expression.
Beta III tubulin is also a structural protein found in neurons. Although tubulin
is expressed widely in a variety of cells, the beta three isoform is particularly
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expressed in neurons. In our experiments conducted here, as found previously
(Blondheim et al., 2006) expression levels in untransfected cells were low. With
introduction of Pax7, Beta III tubulin expression was increased.
Beta III tubulin forms the cytoskeleton structure of the neuron. Studies have
shown that increased expression of Beta III tubulin in neural precursor cells indicates
the formation of neuronal axons (Moskowitz and Oblinger, 1995). Our results are
consistent with the finding by Lee and Pixley; who showed that Beta III tubulin is
particularly expressed in high levels within the somata of new born neurons but shows
little expression in mature neurons (Lee et al., 1990). Thus Beta III tubulin is
implicated in building up of the cytoskeletal structure of differentiating stem cells
towards a neural precursor lineage. Upregulation of Beta III tubulin in Pax7+ stem
cells may indicate that Pax7 is a suitable transcription factor for use in differentiation
of stem cells for transplant therapies. Untransfected BMSSCs however also expressed
Beta III tubulin. Blondheim (Blondheim et al., 2006) who showed similar Beta III
tubulin expression in untransfected BMSSCs and hypothesised that expression of low
levels of neural markers in stem cells indicated their ability to differentiate along a
neurogenic lineage.
Stronger evidence that Pax7 induces neurogenic differentiation in stem cells is
provided by the finding that NeuN was upregulated in transfected cells. NeuN is a
nuclear protein antigen that is used to identify post mitotic neuron (Weyer and
Schilling, 2003). It is used as a marker for neuronal matura~ion in the nervous system
and is predominantly localised to the cell nucleus. Both P19 and NIH3T3 transfected
cells expressed similar patterns of NeuN, indicating that Pax? upregulated NeuN and
induced neural differentiation. NeuN has specific staining patterns; it is preferentially
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found in areas of low chromatin density and virtually excluded from densely packed
DNA (Lind et al., 2005).

GFAP has been used as a biomarker for neuroglial cells, as it is a protein
usually expressed by astrocytes (Hausmann et al., 2000; Maubach et al., 2006). Of
particular note was our ftnding that the expression level of GFAP was dramatically
altered in the presence of the Pax7 protein when assessed by RT-PCR. Thus,
introducing Pax7 represses the expression of GFAP which possibly indicates
repression of an astrocytic lineage (Lee et al., 2006), in transfected differentiating
cells.
The protein level of GFAP appeared unchanged after Pax7 transfection, in
both P19 and NIH3T3 cells, which could be an indication that the turnover rate of
GFAP is slow. The continuing protein expression of GFAP may be an indication that

ubiquitin mediated protein degradation is active at very low levels for GFAP protein.
Other studies have shown that different cellular proteins have variable turnover rates
through ubiquitin mediated protein degradation (Ciechanover, 1991).
The upregulation of Nestin mRNA by Pax7 transfection in P19 cells was an
unexpected result. Nestin is an intermediate ftlament protein that has typically been
associated with neuroepithelial cells and is an indicator of cells at an early stage of
neural differentiation (Dahlstrand et al., 1995). During the development of CNS,
proliferating neuroepithelial cells express Nestin (Lendahl et al., 1990). However,
nestin is no longer considered to be exclusive to neural stem cells but rather is an
indication of a multi potent progenitor cell, as it has also been shown to be expressed
in muscle progenitor cells and some epithelial cells (Mokry and Nemecek, 1998).
Since nestin expression in stem cells bridges the gap between neural progenitor stem
cells and differentiated neurons, Pax7 transfected cells expressing Nestin could be
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said to be on a path towards neural differentiation. BMSSCs also expressed nestin,
which indicates the potential of BMSSCs to differentiate along a neural lineage. Other
studies have shown similar expression of Nestin in BMSSCs (Scintu et al., 2006;
Tondreau et al., 2004).
The continued expression of Nestin in Pax? transfected cells suggested that
even though the cells expressed NeuN and other markers of mature neurons, the cells
were still at an early stage of neural differentiation. Alternatively, Nestin expression
after transfection could be an artefact of culture conditions. This is supported by a
study that showed that the passage number and presence of serum in culture were two
factors that affect expression of nestin (Wislet-Gendebien et al., 2003). Further work
needs to be done to elucidate the reasons for the continued expression of nestin in
Pax7 transfected cells.

Markers of specific dorsal midbrain neurons were consistently increased in
Pax7 transfected cells. Ephrin A2 (Ephrin Alpha receptor 2) is a marker of mature

differentiated neurons in the dorsal midbrain or tectum. Class A Ephrins are protein
coupled receptors that are linked to the cell membrane by a GPI anchor. Ephrin
molecules play a vital role as regulators of developmental processes such as axon
guidance, cell migration and synapse formation (Wilkinson, 2001; Holmberg et al.,
2005). These molecules provide a feedback system for cells at different stages of
maturation and connectivity, and regulate the number of cells generated in the brain.
Upregulation of Ephrin A2 in Pax7 transfected cells

bot~

P19 and NIH3T3 cells,

provided further evidence that transfected cells were undergoing neuronal
differentiation. While Ephrin A2 might not be directly bound by the Pax?
transcription factor, it is certain that its expression is regulated by Pax?. This is
supported by previous studies, which showed that Pax? regulated expression of
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Ephrin A2 in vitro (Thomas et al., 2004) and in vivo (Thompson et al, 2006). Pax7

and ephrin A2 may regulate polarity and topography of the dorsal midbrain. Our
findings here lend further support to these previous studies and indicated that
transfection of stem cells with Pax7 produced a specific midbrain neural progenitor
cell, useful for future stem cell transplant therapies.
Engrailed is also a transcription factor that determines the structure and
polarity of the dorsal midbrain (Itasaki et al., 1991). Expression of Engrailed was
dramatically increased in transfected cells. Up regulation of Engrailed due to the
presence of Pax7 provided further evidence that Pax7 induced differentiation of stem
cells towards a neural lineage specific to the midbrain.
So far we have shown by RT-PCR and immunocytochemistry that Pax7
upregulated key neuronal genes Neurofilament, Engrailed, NCAM, Beta III tubulin
and down regulated astrocytic gene GFAP. The expression profile of these genes
indicated that the transfected cells had differentiated into early stages neurons and not
astrocytes. Increased expression of Ephrin A2 which is a marker for tectal neurons
and NeuN, a mature neuron marker as well as Engrailed provided further evidence
that the differentiated cells were neurons specific to the tectum. Thus Pax7 induced
neurons may ultimately be used as cellular material for transplant therapies in the
tectum.
It is clear from our results that while Pax7 transfected cells expressed

markers of differentiated neurons, they also expressed stem cell markers such as CD
90, CD44 and CD11B. Transfected cells also expressed Ki67, which is a marker of
proliferation. NIH3T3 cells in particular expressed Ki67 after transfection with Pax7,
when growth factors were withdrawn, the expression of proliferation markers
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decreased. Growth factors are known to cause rapid proliferation in stem cells (Villa
et al., 2000). Thus it was clear that transfected cells did not fully differentiate.
It is also now clear that production of a homogeneous population of neurons

is not possible with the use of just one transcription factor. While the cells transfected
with Pax7 showed several characteristic of midbrain neurons, they still retained stem
cell features. This may be an artefact of the stem cell lines used as they are engineered
to remain proliferative. Alternatively, differentiation even in vivo may proceed via
several steps in which markers of both differentiated and undifferentiated cells are
present.
BMSSCs are suitable cellular material for transplant therapies, but they are
difficult to culture. The cells proliferated slowly and when transfected remained
firmly

attached

to

the

plastic,

and

thus

were

not

transferable

into

immunocytochemistry wells. BMSSCs are also affected by small variations in culture
conditions i.e. different serum batches affect growth conditions. Future research will
need to take these factors into consideration to ensure optimal culture conditions of
BMSSCs neural induction.
In summary, in Pax7 transfected cells, neural genes were upregulated and
cells differentiated towards a neural lineage. The key genes upregulated by
transfection of Pax7 were Neurofilament, Beta III tubulin, Engrailed 2, Ephrin A2,
NCAM and NeuN. The cell types produced in two transfected cell lines were similar
strengthening the case for the use of developmental transcription factor to produce
specific neurons in culture.
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6.3

Future directions

Further work is needed to characterise and carefully quantify which genes
are expressed at a basal level in stem cells. Micro-array is a useful tool to assess gene
expression at a basal level. The transfected cells also need further characterisation
before use in cell replacement therapy. Transfection into freshly isolated BMSSCs
may produce more consistent results.
Additional work is also needed to identify the ability of individual Pax7
transcripts to regulate key genes associated with neural cell differentiation. Here, we
only transfected one transcript, Pax7d; two or more transcripts may have yielded
better results.
Research is currently underway to assess the key genes that are regulated by
the transcription factor Pax7 in vivo. This information may be useful in assessing the
molecular mechanisms responsible for cell differentiation towards one lineage and not
another.
Developmental genes are still thought to provide the best possible
mechanism of producing differentiated neurons in vitro for use in stem cell transplant
therapies. Our results provide further support for this theory.
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APPENDIX!

Vector sequence ofpcDNA3.1DN5-His-TOPO vector (Invitrogen)
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGC
CGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCG
AGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTT
AGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGAT
TATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGA
GTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC
CCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC
GTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCA
GTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATT
ACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAAC
GGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTG
TACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACT
GGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGTTAAGCTTGG
TACCGAGCTCGGATCCAGTACCCTTCAC
GGGTCAAGACAATTCTGC
AGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTAAGCC
TATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATT
GAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTG
CCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAA
ATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGG
GGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTG
GGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCG
CCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACA
CTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGC
CGGCTTTCCCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTA
CGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCC
TGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTT
CCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTG
GGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAA
TTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGA
AGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCC
CCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCC
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCT
GACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAA
GTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATA
TCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGAT
GGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCA
CAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCG
GTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCG
CGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTG
AAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTC
ACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCT
TGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTAC
TCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGC
GCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGT
GACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTC
ATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGT
GATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCG
CCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGG
ACTCTGGGGTTCGCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCG
ATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTG
GATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATT
GCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTT
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TTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTAT
ACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAAT
TGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGG
GGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGT
CGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT
TGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTG
CGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGAT
AACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGG
CCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACG
CTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGG
AAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTC
TCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTA
GGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCC
TTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAG
CAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGA
AGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGA
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTG
GTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG
AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGG
GATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGA
AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAA
TCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCC
GTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATA
CCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGG
GCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCC
GGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTAC
AGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGA
TCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTC
CGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCA
TAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCA
AGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGG
ATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGG
GGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC
ACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGA
AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACT
CTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATAT
TTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGC
CACCTGACGTC
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APPENDIX2
The eDNA sequence of Pax7d transcript which was cloned into the vector with
altered nucleotide sequence.
ATGGCGGCGCTGCCCGGCGCGGTCCCCAGGATGATGAGACCCGGCCCGGGGCAGAACTACCCGCGCACC

~AGIGTGGCGACTCCGGATGTGGAG

AAAAAGATTGAGGAGTATAAGAGAGAGAACCCCGGGATGTTCAGCTGGGAAATCCGGGACCGGCTGCTG
AAGGACGGTCACTGCGACCGAAGCACGGTGCCCTCAGpTTTAGif
'•.••GGAACCGTCTGGATGAGGGCTCAGATGTGGAATCA
GAACCCGACCTCCCCCTGAAGCGCAAGCAGCGCCGCAGTCGGACCACGTTCACAGCCGAGCAGCTGGAG
GAGCTGGAGAAGGCCTTCGAGAGGACCCACTACCCGGACATCTACACCCGGGAGGAGCTGGCACAGAGG

• ATGGAGGCAGCACA
GTACACAGGCCCCAGCCCCTTCCGCCATCAACCATGCATCAGGGTGGGCTGGCTGCGGCCGCTGCAGCA
GCGGACACCAGCTCTGCCTACGGAGCCCGCCACAGCTTCTCCAGCTACTCTGACAGCTTCATGAACCCT
GGGGCTCCCTCCAACCACATGAACCCTGTCAGCAATGGCCTGTCTCCTCAG ..

./·1\CTGCTGTTGATTACCTGGCCAAAAACGTGAGCCTGTCCACACAGCGC
CGTATGAAGCTTGGGGAACACTCCGCTGTGCTGGGACTTCTTCCTGTGGAAACGGGACAAGCCTACTAG

Notes:
Pax7.

jCAGI is included in the transcript Pax7d while IGTTTAGI is excluded from
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APPENDIX3
Buffers and solutions

1. lOx Phosphate Buffered Saline (lOx PBS)
Sodium chloride NaC1 ..................................................85g
- Di-hydrogen sodium phosphate .................................. .4g
- Di-sodium hydrogen phosphate .................................. .10.6g
- ddH20 ............................................................................1L
- pH7.4 with cHCl
2. lOx Tris Buffered Saline (lOx TBS)
- TRIS base ......................................................................48g
- Sodium chloride .......................................................... .36g
- ddH20 ............................................................................1L
- pH7 .4 with cHCl

3. lOx Tris Non-Saline (lOx TNS)
- TRIS base ...................................................................... 60g
- ddHzO ............................................................................ lL
- pH7 .4 with cHCl
4. 4% Paraformaldehyde (4% PFA)
- Paraformaldehyde .........................................................40g
- Heat to dissolve PFA
- pH7 .4 with orthophosphoric acid
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